中南大学学报(医学版)
中南大學學報(醫學版)
중남대학학보(의학판)
JOURNAL OF CENTRAL SOUTH UNIVERSITY (MEDICAL SCIENCES)
2014年
12期
1233-1239
,共7页
陈嘉%张燕%邓甘露%马俊丽%吴晓玲%屈雁玲%曾珊
陳嘉%張燕%鄧甘露%馬俊麗%吳曉玲%屈雁玲%曾珊
진가%장연%산감로%마준려%오효령%굴안령%증산
肝癌%含梭基端的张力蛋白样分子%无复发生存时间%总生存时间
肝癌%含梭基耑的張力蛋白樣分子%無複髮生存時間%總生存時間
간암%함사기단적장력단백양분자%무복발생존시간%총생존시간
hepatocellular carcinoma%C-terminal tensin-like protein%recurrence-free survival%overall survival
目的:探讨只含梭基端的张力蛋白样分子(C-terminal tensin-like protein,CTEN)在肝癌中的表达及其与预后的关系。方法:采用免疫组织化学的方法检测240例肝癌患者的癌组织和癌旁组织CTEN蛋白的表达;采用卡方检验、Kaplan-Meier曲线和COX回归模型,对患者CTEN表达与临床病理特征、5年无复发生存期、总生存期以及预后的关系进行统计分析。结果:肝癌组织和癌旁组织CTEN蛋白的阳性高表达率分别为55.0%和20%(P<0.001)。CTEN表达与肝癌肿块大小(P=0.022)、血管侵犯(P=0.007)和TNM分期(P=0.021)正相关。CTEN高表达患者的5年无复发生存期(P<0.001)和总生存期(P<0.001)明显低于CTEN低表达的患者。COX回归分析显示CTEN高表达是肝癌患者术后复发的不良预后因子(P=0.001),也是患者死亡的不良因子(P=0.012)。结论:CTEN蛋白可能在肝癌的发生、发展中发挥作用,是肝癌的不良预后因子。
目的:探討隻含梭基耑的張力蛋白樣分子(C-terminal tensin-like protein,CTEN)在肝癌中的錶達及其與預後的關繫。方法:採用免疫組織化學的方法檢測240例肝癌患者的癌組織和癌徬組織CTEN蛋白的錶達;採用卡方檢驗、Kaplan-Meier麯線和COX迴歸模型,對患者CTEN錶達與臨床病理特徵、5年無複髮生存期、總生存期以及預後的關繫進行統計分析。結果:肝癌組織和癌徬組織CTEN蛋白的暘性高錶達率分彆為55.0%和20%(P<0.001)。CTEN錶達與肝癌腫塊大小(P=0.022)、血管侵犯(P=0.007)和TNM分期(P=0.021)正相關。CTEN高錶達患者的5年無複髮生存期(P<0.001)和總生存期(P<0.001)明顯低于CTEN低錶達的患者。COX迴歸分析顯示CTEN高錶達是肝癌患者術後複髮的不良預後因子(P=0.001),也是患者死亡的不良因子(P=0.012)。結論:CTEN蛋白可能在肝癌的髮生、髮展中髮揮作用,是肝癌的不良預後因子。
목적:탐토지함사기단적장력단백양분자(C-terminal tensin-like protein,CTEN)재간암중적표체급기여예후적관계。방법:채용면역조직화학적방법검측240례간암환자적암조직화암방조직CTEN단백적표체;채용잡방검험、Kaplan-Meier곡선화COX회귀모형,대환자CTEN표체여림상병리특정、5년무복발생존기、총생존기이급예후적관계진행통계분석。결과:간암조직화암방조직CTEN단백적양성고표체솔분별위55.0%화20%(P<0.001)。CTEN표체여간암종괴대소(P=0.022)、혈관침범(P=0.007)화TNM분기(P=0.021)정상관。CTEN고표체환자적5년무복발생존기(P<0.001)화총생존기(P<0.001)명현저우CTEN저표체적환자。COX회귀분석현시CTEN고표체시간암환자술후복발적불량예후인자(P=0.001),야시환자사망적불량인자(P=0.012)。결론:CTEN단백가능재간암적발생、발전중발휘작용,시간암적불량예후인자。
Objective: To explore the correlation between the expression of C-terminal tensin-like protein (CTEN) and the prognosis of hepatocellular carcinoma (HCC). Methods: Using immunohistochemistry, we detected CTEN protein level in samples of primary lesion and adjacent non-tumor lesion collected from 240 patients with HCC. The relationship between CTEN expression and clinicopathology, 5 year recurrent-free survival, or overall survival was evaluated by Chi-square test, Kaplan-Meier, or Cox regression analysis. Results: High CTEN expression was detected in 55% of hepatocellular carcinoma tissues and 20%of adjacent carcinoma tissues (P<0.001). CTEN expression was positively correlated with tumor diameter (P=0.022), venous invasion (P=0.007) or TNM stages (P=0.022). Five-year recurrence-free survival time (P<0.001) and overall survival time (P<0.001) in patients with high CTEN expression were signiifcantly less than those in patients with low CTEN expression. Multivariate Cox regression analysis revealed that the CTEN expression was an independent prognostic marker for HCC (all P<0.05). Conclusion: CTEN protein may play a role in the genesis and development of HCC, and it can function as a prognostic marker.